AHFS April 2022 Update

This update contains 3 new monographs and 61 revised monographs.

New monographs: Abrocitinib; Bebtelovimab; Faricimab

Revised monographs: Alprostadil; Alteplase; Amantadine; Amiodarone; Apremilast; Argatroban; Asparaginase (Erwinia chrysanthemi) (recombinant)-rywn; Avatrombopag; Belzutifan; Benztropine; Bumetanide; Cisatracurium; Dasatinib; Dexmedetomidine; dilTIAZem; Diroximel Fumarate; DOBUTamine; Dopamine; Dostarlimab-gxly; Eltrombopag; Epinephrine; Esmolol; Etanercept; fentaNYL; Furosemide; Heparin; HYDROmorphone; Ibrutinib; Insulin Human; Isoproterenol; Ketamine; Labetalol; LORazepam; Midazolam; Milrinone; Morphine; Naloxone; niCARdipine; Norepinephrine; Octreotide; Osimertinib; Pantoprazole; PENTobarbital; Phenylephrine; Pralsetinib; Propofol; Remifentanil; Ripretinib; Rocuronium; Sodium Bicarbonate; Sodium Chloride; Sodium Nitroprusside; Sonidegib; Temozolomide; Tepotinib; Terbutaline; Tranexamic Acid; Umbralisib; Vasopressin; Vecuronium; Venetoclax